MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-17-2026
Aeterna Zentaris Market Cap 2011-2026 | AEZS
As of January 21, 2026 Aeterna Zentaris has a market cap of $ 314 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Aeterna Zentaris
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 41.4 M | 28.3 M | 18.7 M | 63 M | 32.3 M | 26.9 M | 3.99 B | 31.3 M | 38.6 M | 59.9 M | 158 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.99 B | 18.7 M | 408 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
87.8 M | $ 1.9 | -3.11 % | $ 107 M |  China |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.71 | 1.88 % | $ 17 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 25.87 | -0.79 % | $ 1.25 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.31 | -4.06 % | $ 7.96 B |  Australia |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.97 | 3.12 % | $ 908 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 215.29 | 4.59 % | $ 5 B |  Danmark |
 |
BioNTech SE
BNTX
|
62.9 B | $ 105.97 | -2.78 % | $ 27.2 B | Germany |
 |
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Bio-Path Holdings
BPTH
|
2.94 M | - | - | $ 100 K | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 64.74 | 1.41 % | $ 8.66 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 3.96 | -1.0 % | $ 8.62 B | Israel |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 9.63 | -0.93 % | $ 1.56 B | Britain |
 |
CASI Pharmaceuticals
CASI
|
1.09 B | $ 0.95 | -0.72 % | $ 129 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 25.15 | -1.95 % | $ 1.62 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 14.01 | 3.7 % | $ 922 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
19.3 B | $ 164.87 | 0.27 % | $ 24 B | USA |
 |
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | USA |
 |
BioVie
BIVI
|
2.44 M | $ 1.23 | 2.07 % | $ 1.82 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.44 B | $ 23.32 | 2.71 % | $ 2.76 B | USA |
 |
Calithera Biosciences
CALA
|
960 M | - | -10.95 % | $ 876 K | USA |